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The transforming properties of human
papillomavirus oncoproteins
Abstract
Human papillomaviruses (HPV) are very common viruses, often caus-
ing benign epithelial lesions but, rarely, also cancer. Only long persistent in-
fection with some carcinogenic or high risk HPV types will progress to
high-grade lesions and finally cancer. The oncogenic potential of these HR
HPV types relies on the role of their major oncoproteins E6 and E7, which
bind, inactivate and degrade the two major cellular tumor-suppressor gene
products, p53 and the retinoblastoma tumor-suppressor protein (pRb),
respectively. The continuous expression of these early oncoproteins can lead
to the transformation and immortalization of infected cells. Both, E6 and
E7 co-operate to induce transformation of epithelial cells by interacting
with numerous host cell proteins affecting many essential cellular pathways.
Herein, the current knowledge on HPV E6 and E7, as well as on the
auxiliary E5 oncoprotein is summarized.
INTRODUCTION
Human papillomaviruses (HPV) belong to a family of Papilloma-viridae, which are circular double-stranded DNA viruses. There
are strictly epitheliotropic infecting either mucosa (Alphapapilloma-
viruses) or skin (Betapapillomaviruses). There are more than 100 HPV
genotypes, of which approximately 40 types infect the anogenital tract
mucosa, while the others infect the cutaneous tissues. Most HPV types
cause benign epithelial proliferation, while others cause cancer. There-
fore, they are classified according to their oncogenic potential into low-
-risk (LR) HPV types and high-risk (HR) or carcinogenic types (Table 1)
(1). The most common LR HPV types 6 and 11 are causing almost 90 %
of genital warts (flat and acuminata condylomata), while the most com-
mon HR HPV types 16 and 18 are causing more than 70 % cervical
cancer cases and most other anogenital cancer as well as oropharyngeal
tumours in men and women (reviewed in (2)).
The HPV genome contains several early and late open reading
frames coding for replication and transcription regulating proteins, E1,
E2, E5, E6, E7 and viral capsid proteins, L1 and L2, respectively (Table
2). Two early proteins, E6 and E7 act as a major viral oncoproteins,
while the E5 acta as an auxiliary oncoprotein (1).
Both E6 and E7 are small proteins, approximately 18 and 13 kDa in
size, respectively, localized in the nucleus (3). The E6 proteins are also
found in the cytoplasm and the E7 probably also has a cytoplasmic
component (4). The expression of the HR E7 proteins by themselves
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can immortalize human keratinocytes at a low frequency
but E6 has no such activity. The combination of E6 and
E7, however, is highly efficient at transforming and im-
mortalizing most types of primary cells (5). In addition
to E6 and E7, the E5 oncoprotein plays an auxiliary role
in cell transformation. Both HR and LR HPV oncopro-
teins bind they target proteins but HR do it with higher
affinity and in addition often degrade them unlike to LR
HPV oncoproteins (6).
The transforming properties of HPV oncoproteins lie
in the interaction with numerous host cell proteins re-
sulting in the maintenance and the re-entering into the
cell cycle, which consequently allows the virus to repli-
cate as it is dependent on the host cell DNA replication
machinery. In addition, the E7 protein, together with the
E6 oncoprotein of the HR HPV types, is able to interfere
with key cellular processes, such as cell cycle, senescence,
differentiation, apoptosis and telomere shortening. Furt-
hermore, because of the frequent integration of the HR
HPV genome into a host cell chromosome, those two
proteins are the only viral proteins that are consistently
expressed in HPV associated cancers (2). The HPV E6
and E7 proteins also associate with enzymes that mo-
dulate histone acetylation and thus, broadly regulate the
transcriptional competence of host cell chromatin (7). In
this review, the interactions of HR HPV oncoproteins
with cellular target proteins are described.
E6 ONCOPROTEINS
The E6 protein is a small (158 amino acid) onco-
protein found in all human papillomavirus genomes (8).
The HR E6 protein is one of the most studied HPV
proteins due to its many functions (reviewed in (9, 10))
and is found to be interacting with many host cell pro-
teins despite its limited size (Table 3). One of the most
well known functions of E6 protein is inactivation and
degradation of the human p53 tumor-suppressor protein
(11). In normal cells p53 is activated upon DNA damage
and either activates pathways leading to reparation of
DNA damage or activates apoptosis or senescence. Di-
verse functions of p53 have most recently been reviewed
by Reinhardt et al. (12). Inactivation of p53 is necessary
for HPV to allow intensive viral DNA replication in the
later stages of viral life cycle (13) that would otherwise be
prevented by p53 activity (Figure 1).
An important control mechanism of the cell cycle oc-
curs during the cell cycle G2-phase, when p53 plays a
crucial role during DNA replication. Usually, p53 is main-
tained at low concentrations by the MDM2-mediated
degradation but when replication errors or other DNA
damages occurs, the checkpoint kinases CHK1 and CHK2
induce increased p53 activity by phosphorylation of va-
rious downstream molecules, including p53 itself. The
p53 tetramer acts as a stress-induced transcription factor
and induces the expression of p21CIP (p21), which inhi-
bits several cyclin-CDK complexes and stops the cell
cycle allowing correction of DNA errors or induction of
apoptosis if the damage is too extensive. Besides its cru-
cial role in cell cycle control, p53 is also a master regulator
of many other stress-associated cellular functions, and is
therefore often inactivated or mutated in many different
cancer types (14).
The HR HPV E6 protein targets the p53 protein for
proteasomal degradation via interaction with the E6-AP
protein (15). However, this is not the only strategy HPV
has for inactivating p53 pathway via E6 protein. Thus,
HPV E6 proteins additionally target proteins both up-
stream and downstream of p53. The HPV E6 was found
to be interacting with hADA3, GPS2, p150(Sal-2), CBP
and p300 all of which proteins act on p53 expression or
help in expression of p53 downstream targets (16–19).
Furthermore, the HPV E6 interferes with different apop-
tosis pathways by additional interactions with BAK, pro-
caspase-8, TIP60, DFF40, FADD, GADD34 and TNFR-1
proteins (20–26).
One of the major roles of HPV E6 is to modulate the
structure of the epithelial tissue to allow for its life cycle
completion in the virus modified upper layer cells where
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TABLE 1
Human papillomvirus (HPV) types and their oncogenic potential (reviewed in (1))
Group Types Oncogenic evidence
Alpha HPV
1
16 Most potent type, causing cancer at several sites
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 Sufficient evidence for cervical cancer
2A 68 Strong evidence for cervical cancer
2B
26, 53, 66, 67, 70, 73, 82 Limited evidence for cervical cancer
30, 34, 69, 85, 97 Phylogeneticly related to types with sufficient or limited evidence
3 6, 11 Insufficient evidence
Beta HPV
2B 5, 8 Limited evidence for skin cancer in patients with epidermodysplasia verruciformis
3 Other beta and gamma types Insufficient evidence
DNA synthesis normally doesn’t take place. Thus, the E6
protein is found to interact with many proteins involved in
cell-cell adhesion, cell-cell interaction and cell polarity
mediating proteins (hDlg, scribble, MAGI-1/2/3, MUPP1,
PATJ, PTPN3) (27–33), mostly via binding to the PDZ
domain in those proteins and to several proteins involved
in epithelial organization and differentiation (fibulin-1,
paxillin, zyxin, E6-BP) (34–37). It is known that HPV
DNA replication induces DNA damage responses in the
cells where the virus is replicating (38), but the E6 pro-
tein itself interacts with several proteins directly involved in
DNA repair like BRCA1, XRCC1 and MGMT (39–41). In
addition, the E6 proteins directly and indirectly target
other proteins involved in chromosomal and DNA sta-
bility like hTERT, MCM7 and NFX1 (42–44).
The expression of E6 protein in cell culture expe-
riments has also found direct and indirect transcriptional
modulation of several host cell promoters: c-myc, pro-
thymosin alpha (45), E-cadherin (46) involucrin (47) that
further deregulate cell cycle control and epithelial orga-
nization. Considering the fact that HPV E6 proteins in-
teract with many less well understood transcriptional
modulating proteins (E6-TP1, MAML1, TRIP-Br1) (48–51)
or proteins involved in signal transduction (NHERF1,
PKN1, TIP-2/GIPC) (52–54), it is certain that many
more promoters are directly and indirectly affected by
HPV oncoproteins in infected cells.
The E6 protein can either only interact (BRCA1, CASP8
(Procaspase 8), E6BP, FADD, fibulin-1, karyopherin (Kap)
alpha2 adapter, MAML1), inhibit (CBP/p300, DFF40,
GADD34/PP1, IRF-3, PATJ, paxillin, TNFR-1, tyk2,
XRCC1), degrade (bak, CAL, DLG, E6TP1, GPS2,
MAGI-1/3, MCM7, MGMT, MUPP1 (MPDZ), NFX-1,
NHERF1, p53, PTPN3, scribble, TIP-2/GIPC, TIP60,
tuberin), activate (E6AP, hTERT, PKN1(PKN), TRIP-
-Br1) or change localisation (Zyxin). Each of this protein-
-protein action induces different effects in the HPV infected
cell through mostly either signal transduction or repli-
cation and transcription modulation (listed in Table 3).
Finally, the E6 protein also appears to have some role
in immune evasion as it interacts with IRF-3 and tyk-2
proteins both of which are involved in interferon sig-
nalling (55, 56).
E7 ONCOPROTEINS
The E7 protein is the major transforming protein of
HPV and shares sequence and structural homology with
adenovirus E1A protein. Based on this homology, the E7
protein can be divided into three domains: conserved
region 1 (CR1, residues 2–15), conserved region 2 (CR2,
residues 16–38), which contains the LXCXE motif re-
quired for high-affinity binding to retinoblastoma pocket
protein (pRb or RB) and other 'pocket proteins' (Table 4),
and conserved region 3 (CR3, residues 39–98). CR3 shows
little sequence homology to adenovirus E1A but like
CR3 of E1A forms a zinc finger structure. However, the
E7 protein shares transformation and transactivation
functions with E1A protein (57).
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The key activity of the E7 protein is to overcome
tumour suppressor block controlled by the pRb, while
those of E6 protein is to overcome the p53 protective
control pathways, which are important in preventing the
genetic damage leading to cellular transformation (Fig-
ure 1). Thus, these oncoproteins promote genetic insta-
bility through induction of cellular proliferation, dis-
ruption of cell cycle checkpoints, inhibition of apoptosis,
induction of telomerase activity and finally lead to cancer
(2). It is clear that high-affinity of E7 protein binding to
pRb is not sufficient for transformation and that regions
outside the pRb-binding domain must be important for
the transforming potential of HR HPV E7 protein. How-
ever, how these regions contribute to transformation is
poorly understood (7).
In quiescent cells, pRb is present in a hypophos-
phorylated form and associates with E2F transcription
factor, thereby inhibiting their transcriptional activity.
Under exposure to a mitogenic signal, complexes of cyc-
lin and cyclin-dependent kinase (CDK) are activated,
notably cyclin D1-CDK4 and cyclin D1-CDK6 com-
plexes, which induce pRb phosphorylation leading to the
disruption of pRb/E2F complexes. Such activated E2F
transcription factors then induce cyclin E and subse-
quent additional phosphorylation of pRb by cyclin E/CDK2
complex that initiates entry into cell cycle S-phase. The
protein p16INK4A (p16) mediates senescence and differen-
tiation by inhibiting cyclin D1/CDK4 and cyclin D1/CDK6
complexes. The interplay between the cyclins, CDKs
and their inhibitors determines whether the restriction
point can be passed (14).
The E7 binding to pRb, and its related members
(p107 and p130) (Table 4), mimics the effects of pRb
phosphorylation resulting in the release of active E2F
transcription factors, which in turn activate the trans-
cription of a group of genes encoding proteins essential
for cell cycle progression. Thus, E7 expressing cells can
enter the S phase in the absence of mitogenic signals
(14). The E7 also binds and activates complexes of cyc-
lins and CDKs, which control progression through the
cell cycle. On the other hand, E6 associates with the
ubiquitin-protein ligase E6AP, which then binds to p53
and targets the p53 protein for multi-ubiquitination and
consequent proteasomal degradation (11). HPV onco-
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TABLE 3
HPV E6 oncoprotein interaction.
Host cell protein Activity Role in cell Reference
p53 Transcription factor Apoptosis and chromosomal stability (11)
BAK Interaction with BCL2 Apoptosis (20)
CASP8 Proteolytic activation Apoptosis (21)
DFF40 DNA fragmentation and
chromatin condensation
Apoptosis (23)
FADD Signal transduction Apoptosis (22)
GADD34/PP1, TIP60 Translation modulation Apoptosis (24), (26)
TNFR-1 Signal transduction Apoptosis TNF alpha signalling (25)
MUPP1 (MPDZ), Zyxin, E6BP Signal transduction Cell-cell contact (30), (36), (37)
TRIP-Br1 Translation modulation Cell cycle (50)
hTERT, MCM7 RNA-directed DNA polymerase
activity, replication factor
Chromosomal stability (44), (42)
NFX-1 Translation modulation Chromosomal stability hTERT regulation (43)
PKN1 (PKN), NHERF1 signal transduction Cytoskeleton, wnt signalling (53), (52)
BRCA1, XRCC1 DNA binding DNA repair (39), (40)
MGMT Cysteine methyltransferase DNA repair (41)
karyopherin (Kap) alpha2 adapter Nuclear protein import E6 nuclear entry (90)
E6TP1, TIP-2/GIPC Signal transduction G protein-linked signalling (48), (54)
PTPN3 Signal transduction Growth hormone signalling (32)
IRF-3, tyk2 Signal transduction Immunity, JAK-STAT signalling (56), (55)
tuberin Signal transduction mTORC1 signalling (51)
MAML1 Translation modulation NOTCH signalling differentiation (49)
p150(Sal2) Translation modulation p53/p21 signalling (19)
ADA3, CBP/p300, GPS2, Translation modulation p53 transcription (16), (17), (36)
fibulin-1, MAGI-1/3 Cell adhesion and migration Cell-cell contact and polarity (34), (29)
DLG, PATJ, paxillin, scribble Signal transduction Cell-cell contact and polarity (27), (33), (35), (28)
E6AP Ubiquitin ligase Ubiquitination of p53 (15)
CAL Intracellular trafficking Vesicular trafficking autophagy (91)
proteins E7 and E6, both have multiple other functions
by binding numerous target proteins and degrading some
via proteasomal degradation, i.e. family proteins of pRb
(p107, p130) (58), and p53 (p63, p73) (11), and p21(CIP1)
protein (59).
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TABLE 4
HPV E7 oncoprotein interaction.
Host cell protein Activity Role in cell Reference
pRb family proteins
(RB, p107, p130)
Tumour suppressor Disruption of pRb–E2F complexes thereby initiating the E2F
mediated transcription
(14)
p21 Cell cycle regulator Binding to and subsequent inactivation of the CDK inhibitor p21 (14)
p27 Cell cycle regulator Binding to and subsequent inactivation of the CDK inhibitor p27 (92)
Cyclins A, E Cell cycle regulators Regulation of cell cycle binding through pRb, p107, respectively (93) (94)
AP1 Transcription Interaction with and transactivation of the AP1 family (95)
TBP Transcription Deregulation of the TBP mediated transcription (96)
MPP2 Transcription Activation of MPP2-specific transcriptional activity (97)
HDAC (Mi2b) Deacetylation Disruption of pRb–HDAC complex (7)
IRF1 Interferon regulation Abrogation of transactivation function of IRF1 (98)
IGFBP-3 Cell growth Inactivation of IGFBP-3 contribute to cell transformation (99)
E2F6 Transcriptional repressor Inactivation of E2F6 leading to extended S-phase of cell cycle (100)
KDM6A, KDM6B Demethylaton Demethylaton of promoters of genes for pRb and p16INK4A,
respectively
(60)
Skip Transcription Inhibition of Skip function contribute to cell transformation (101)
M2PK Glycolytic
phosphometabolism
Transforming cells by modulation of type M2 pyruvate kinase
activity
(102)
GAA Carbohydrate metabolism Induces the catalytic activity of acid á-glucosidase (103)
NHERF-1 (Na+/H+
exchange regulatory
factor 1)
Cell signalling NHERF-1 degradation that correlates with the activation of the
phosphatidylinositol-3’-OH kinase (PI3K)/AKT signalling
pathway
(104)
p48 Immune evasion Down-regulation of IFN á-mediated signal transduction (105)
p300, pCAF Transcription Abrogates p300 and pCAF associated HAT activity (62)
SRC1 Steroid hormone signalling Abrogates SRC1 associated HAT activity (61)
p600 Regulator of anoikis Inhibition of anoikis thereby protect from apoptosis (65)
Figure 1. Essential interaction of HR HPV E5, E6 and E7 oncoproteins and consequences in the infected cell. E7 proteins induce hyperproliferation
through inhibition of retinoblastoma (RB) family members and constitutive activation of E2F-responsive genes. E6 proteins inhibit p53-dependent
growth arrest and apoptosis. E5 contributes to the actions of E6 and E7 by modulating the transit of signalling proteins through the endoplasmic
reticulum. In addition to aberrant proliferation and lack of apoptosis, there is an accumulation of cellular mutations and increased genomic
instability resulting with cellular transformation leading to immortalisation
In addition, the HR HPV E7 binds histone deacety-
lase (HDAC) in a pRb-independent manner. HDAC
binds to the zinc finger region of E7. This zinc finger
region specifically binds Mi2b, a component of a HDAC
complex, which finally disrupts the Rb–HDAC complex.
Both Rb binding and Mi2b/HDAC binding are neces-
sary for E7 to promote cell growth (7).
Furthermore, the HR HPV E7 induces KDM6B and
its transcriptional target, cervical carcinoma biomarker,
p16INK4A, the process is not dependent on pRb inactiva-
tion and hence, is not linked to E2F activation (60).
Because the HR HPV E7 simultaneously inactivates the
critical mediator of p16INK4A induced senescence, pRb,
HR HPV E7-expressing cells escape senescence and con-
tinue to proliferate, and several known KDM6A- or
KDM6B-regulated HOX genes (Homeobox; master re-
gulators of transcriptional programs that maintain cellu-
lar identities) are expressed at higher levels in such cells.
Hence, the HR HPV E7 expression causes epigenetic
reprogramming of host cells at the level of histone meth-
ylation (60).
The E7 protein can also associate, directly or indirect-
ly, with histone acetyl transferases (HATs) including p300,
pCAF, and SRC1 (Steroid Receptor Coactivator 1; es-
sential component of steroid hormone signalling) (61)
(62). It has been shown that HR HPV E7 abrogates
SRC1 associated HAT activity (61).
Some studies have suggested that E7 promotes telo-
mere lengthening through the alternative lengthening of
telomeres (ALT) pathway, which involves homologous
recombination between telomere sister chromatids (63).
It is possible that the activation of ALT by E7 is im-
portant in maintaining telomere length early in cancer
development. This would allow growth of cells that
maintain a minimal level of telomerase activity, and is
consistent with the notion that E6 plays a part in tumour
progression by primarily promoting telomerase activity
in high-grade cervical lesions and carcinomas (3).
The p600 protein is a regulator of process of anoikis, a
form of apoptosis that is induced by inadequate or in-
appropriate cell-matrix interactions (64). The HR and
LR HPV E7 proteins associate with pRb-associated pro-
tein p600 (65) results in anoikis resistance in different
cell types. Thus, the interaction between E7 and p600
inhibit anoikis and protect detached cells from apoptosis,
thereby contributing to viral transformation (65) (66).
The HR HPV E7 expression also causes mitotic ab-
normalities including chromosomal fusions caused by
double stand DNA breaks (67). The presence of DNA
repair foci seen in the HR HPV E7 expressing cells
indicates that E7 may induce double strand DNA breaks
or interfere with break repair. This facilitates viral genome
integration, which pointed out E7 as a driving force for
the genome integration of HR HPV types into host cellular
chromosomes, event that frequently accompanies ma-
lignant progression of HR HPV associated lesions (4). In
addition to centrosome abnormalities, the E6 and the E7
proteins have been shown to independently bypass mito-
tic checkpoints, resulting in the accumulation of poly-
ploid cells that can lead to aneuploidy. Abrogation of
these checkpoints may be important for viral replication
but can also lead to genomic instability in HPV-im-
mortalized cells (3).
E5 ONCOPROTEIN
The E5 oncoprotein is the least studied of the papillo-
mavirus oncoproteins. This very small protein of only 83
amino acids (68) is not well conserved among different
papillomaviruses (69). It is the major oncoprotein of the
bovine papillomaviruses and in human papillomaviru-
ses acts as a supplementary oncoprotein. The protein is
highly hydrophobic and associates with the Golgi appara-
tus endoplasmic reticulum and nuclear membrane (70).
All known functions of the E5 oncoprotein were most
recently reviewed by Venute et al. (71). Briefly, E5 is
known to reduce the expression of surface HLA mole-
cules leading to improved immune evasion (72). This is
mediated by a direct interaction of HLA molecules and
E5 proteins, which leads to MHC accumulation in Golgi
and reduction on the surface (73). Furthermore E5 in-
teracts directly with Bap31 protein (74) that is also in-
volved in vesicular trafficking and MHC molecule deli-
very to the cell surface (75). Another mechanism of the
E5 immune evasion is the over expression of gangliosides
on the cell surface, which prevents immunological re-
cognition by T-cells (76). The E5 protein was also found
to induce the degradation of Bax and thus have an anti-
apoptotic role in viral infection (77)
The HR HPV E5 was shown to interact with the 16
kD unit of vacuolar ATPase (78) and that this interaction
prevents vacuolar acidification, which is supposed to
allow better EGF receptor recycling and influence growth
factor response and signalling (79). On the other hand
BVP1 E5 was shown to directly bind PDGF receptor and
activate it without any ligand present (80).
CONCLUSION
The two most important interactions of HR HPV E6
and E7 oncoproteins leading to cell transformation and
immortalisation are the binding and degradation of the
major tumor-suppressors p53 and pRb, respectively. In
addition to many other herein described protein-protein
interactions of E6 and E7 oncoproteins, HPV was also
found to modulate several important cell signalling path-
ways such as: mTORC signalling (81), WNT signalling
(82), TGF-beta signalling (83), HER/PTEN/Akt path-
way (84), ERK-MAP pathway (85), ATM DNA Damage
pathway (86), NOTCH-1 signalling (87), WNT signal-
ling (88), TGF-b signalling (88), calcium signalling (88),
MAPK signalling (88) and insulin signalling (89). This
list of protein-protein interactions is probably not complete
and future research will probably reveal new pathway
targets and enable better understanding of HPV-mediat-
ed carcinogenesis.
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